ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 24 filers reported holding ALPINE IMMUNE SCIENCES INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $956,000 | -40.7% | 248,992 | -38.8% | 0.03% | -53.0% |
| Q3 2019 | $1,611,000 | -8.0% | 406,926 | -2.2% | 0.07% | +4.8% |
| Q2 2019 | $1,751,000 | -46.3% | 415,908 | -12.5% | 0.06% | -49.6% |
| Q1 2019 | $3,262,000 | +86.4% | 475,450 | 0.0% | 0.12% | +78.6% |
| Q4 2018 | $1,750,000 | -54.9% | 475,450 | -22.4% | 0.07% | -49.6% |
| Q3 2018 | $3,879,000 | -43.9% | 612,867 | -32.9% | 0.14% | -42.8% |
| Q2 2018 | $6,912,000 | -5.4% | 913,100 | 0.0% | 0.24% | -4.0% |
| Q1 2018 | $7,305,000 | -28.6% | 913,100 | 0.0% | 0.25% | -37.1% |
| Q4 2017 | $10,227,000 | -5.5% | 913,100 | -2.1% | 0.40% | -17.6% |
| Q3 2017 | $10,824,000 | – | 933,100 | – | 0.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 4,708,288 | $42,233,000 | 12.94% |
| Lynx1 Capital Management LP | 1,484,693 | $13,318,000 | 12.36% |
| Omega Fund Management, LLC | 2,029,580 | $18,205,000 | 3.73% |
| TCG Crossover Management, LLC | 1,034,222 | $9,277,000 | 3.72% |
| Frazier Life Sciences Management, L.P. | 4,185,757 | $37,546,000 | 3.20% |
| Paradigm Biocapital Advisors LP | 336,229 | $3,016,000 | 0.80% |
| Orbimed Advisors | 4,081,592 | $36,612,000 | 0.59% |
| BVF INC/IL | 1,589,495 | $14,258,000 | 0.57% |
| Kingsbury Capital Investment Advisors LLC | 29,153 | $262,000 | 0.29% |
| Avidity Partners Management LP | 1,207,000 | $10,827,000 | 0.22% |